These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 18622373)
1. [Pilot study on M2-PK-- a new non-invasive parameter for early diagnosis of colorectal carcinoma]. Ivanova A; Iarŭmov N; Toshev S; Adzharov D; Krŭstev Z; Angelov K; Sokolov M; Gribnev P Khirurgiia (Sofiia); 2007; (6):5-7. PubMed ID: 18622373 [TBL] [Abstract][Full Text] [Related]
2. [Faecal pyruvate kinase type M2--a valid screening parameter for colorectal cancer? Preliminary results from a multicenter comparative study]. Naumann M; Schaum B; Oremek GM; Hanisch E; Rösch W; Mössner J; Caspary WF; Stein J Dtsch Med Wochenschr; 2004 Aug; 129(34-35):1806-7. PubMed ID: 15314744 [No Abstract] [Full Text] [Related]
3. [Pyruvate kinase M2 (tumor M2-PK) as a screening tool for colorectal cancer (CRC). A review of current published data]. Ewald N; Toepler M; Akinci A; Kloer HU; Bretzel RG; Hardt PD Z Gastroenterol; 2005 Dec; 43(12):1313-7. PubMed ID: 16315127 [TBL] [Abstract][Full Text] [Related]
4. Comparison of a novel fecal marker--fecal tumor pyruvate kinase type M2 (M2-PK) with fecal calprotectin in patients with inflammatory bowel disease: a prospective study. Shastri YM; Povse N; Schröder O; Stein J Clin Lab; 2008; 54(9-10):389-90. PubMed ID: 19097497 [No Abstract] [Full Text] [Related]
5. Measurement of fecal pyruvate kinase type M2 (tumor M2-PK) concentrations in patients with gastric cancer, colorectal cancer, colorectal adenomas and controls. Hardt PD; Toepler M; Ngoumou B; Rupp J; Kloer HU Anticancer Res; 2003; 23(2A):851-3. PubMed ID: 12820312 [TBL] [Abstract][Full Text] [Related]
6. Fecal pyruvate kinase concentrations (ELISA based on a combination of clone 1 and clone 3 antibodies) for gastric cancer screening. Hardt PD; Toepler M; Ngoumou B; Rupp J; Kloer HU Anticancer Res; 2003; 23(2A):855-7. PubMed ID: 12820313 [TBL] [Abstract][Full Text] [Related]
7. Comparison of faecal M2-PK and FIT in a population-based bowel cancer screening cohort. Leen R; Seng-Lee C; Holleran G; O'Morain C; McNamara D Eur J Gastroenterol Hepatol; 2014 May; 26(5):514-8. PubMed ID: 24699725 [TBL] [Abstract][Full Text] [Related]
8. [Comparison of different stool tests for the detection of cancer of the colon]. Vogel T; Driemel C; Hauser A; Hansmann A; Lange S; Jonas M; Möslein G Dtsch Med Wochenschr; 2005 Apr; 130(14):872-7. PubMed ID: 15800820 [TBL] [Abstract][Full Text] [Related]
9. Fecal pyruvate kinase-M2 (tumor M2-PK) measurement: a new screening concept for colorectal cancer. Ewald N; Schaller M; Bayer M; Akinci A; Bretzel RG; Kloer HU; Hardt PD Anticancer Res; 2007; 27(4A):1949-52. PubMed ID: 17649802 [TBL] [Abstract][Full Text] [Related]
10. Tumor M2-pyruvate kinase: a promising tumor marker in the diagnosis of gastro-intestinal cancer. Hardt PD; Ngoumou BK; Rupp J; Schnell-Kretschmer H; Kloer HU Anticancer Res; 2000; 20(6D):4965-8. PubMed ID: 11326648 [TBL] [Abstract][Full Text] [Related]
11. Tumor pyruvate kinase isoenzyme type M2 and immunochemical fecal occult blood test: performance in screening for colorectal cancer. Mulder SA; van Leerdam ME; van Vuuren AJ; Francke J; van Toorenenbergen AW; Kuipers EJ; Ouwendijk RJ Eur J Gastroenterol Hepatol; 2007 Oct; 19(10):878-82. PubMed ID: 17873612 [TBL] [Abstract][Full Text] [Related]
12. Correlation between Faecal Tumour M2 Pyruvate Kinase and Colonoscopy for the Detection of Adenomatous Neoplasia in a Secondary Care Cohort. Bond AD; Burkitt MD; Sawbridge D; Corfe BM; Probert CS J Gastrointestin Liver Dis; 2016 Mar; 25(1):71-7. PubMed ID: 27014756 [TBL] [Abstract][Full Text] [Related]
13. Colorectal cancer screening by non-invasive metabolic biomarker fecal tumor M2-PK. Tonus C; Neupert G; Sellinger M World J Gastroenterol; 2006 Nov; 12(43):7007-11. PubMed ID: 17109496 [TBL] [Abstract][Full Text] [Related]
14. The Usefulness of a Novel Screening Kit for Colorectal Cancer Using the Immunochromatographic Fecal Tumor M2 Pyruvate Kinase Test. Kim YC; Kim JH; Cheung DY; Kim TH; Jun EJ; Oh JW; Kim CW; Chung WC; Kim BW; Kim SS; Kim JI; Park SH; Kim JK Gut Liver; 2015 Sep; 9(5):641-8. PubMed ID: 25473070 [TBL] [Abstract][Full Text] [Related]
15. Faecal tumour pyruvate kinase M2: not a good marker for the detection of colorectal adenomas. Shastri YM; Stein JM Br J Cancer; 2008 Oct; 99(8):1366; author reply 1367. PubMed ID: 18827821 [No Abstract] [Full Text] [Related]
16. [Clinical significance of blood and fecal tumor M2-pyruvate kinase expression in patients with colorectal cancer]. Li Y; Wang JJ Nan Fang Yi Ke Da Xue Xue Bao; 2011 Dec; 31(12):2087-9. PubMed ID: 22200720 [TBL] [Abstract][Full Text] [Related]
17. New faecal tests in gastroenterology. Ayling RM Ann Clin Biochem; 2012 Jan; 49(Pt 1):44-54. PubMed ID: 22113956 [TBL] [Abstract][Full Text] [Related]
18. Prospective multicenter evaluation of fecal tumor pyruvate kinase type M2 (M2-PK) as a screening biomarker for colorectal neoplasia. Shastri YM; Naumann M; Oremek GM; Hanisch E; Rösch W; Mössner J; Caspary WF; Stein JM Int J Cancer; 2006 Dec; 119(11):2651-6. PubMed ID: 16929517 [TBL] [Abstract][Full Text] [Related]
19. Tumor type M2-pyruvate-kinase levels in pleural fluid versus plasma in cancer patients: a further tool to define the need for invasive procedures. Elia S; Massoud R; Guggino G; Cristino B; Cortese C; De Massimi AR; Zenobi R Eur J Cardiothorac Surg; 2008 Apr; 33(4):723-7. PubMed ID: 18261916 [TBL] [Abstract][Full Text] [Related]
20. Fecal dimeric M2-pyruvate kinase (tumor M2-PK) in the differential diagnosis of functional and organic bowel disorders. Jeffery J; Lewis SJ; Ayling RM Inflamm Bowel Dis; 2009 Nov; 15(11):1630-4. PubMed ID: 19462434 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]